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Abstract: Dronedarone is an amiodarone analog but differs structurally from amiodarone in that the iodine moiety was removed and a 
methane-sulfonyl group was added. These modifications reduced thyroid and other end-organ adverse effects and makes dronedarone 
less lipophilic, shortening its half-life. Dronedarone has been shown to prevent atrial fibrillation/flutter (AF/AFl) recurrences in sev-
eral multi-center trials. In addition to its rhythm control properties, dronedarone has rate control properties and slows the ventricular 
response during AF. Dronedarone is approved in Europe for rhythm and rate control indications. In patients with decompensated heart 
failure, dronedarone treatment increased mortality and cardiovascular hospitalizations. However, when dronedarone was used in elderly 
high risk AF/AFl patients excluding such high risk heart failure, cardiovascular hospitalizations were significantly reduced and the drug 
was approved in the USA for this indication in 2009 by the Food and Drug Administration. Updated guidelines suggest dronedarone 
as a front-line antiarrhythmic in many patients with AF/Fl but caution that the drug should not be used in patients with advanced heart 
failure. In addition, the recent results of the PALLAS trial suggest that dronedarone should not be used in the long-term treatment of 
patients with permanent AF.
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Introduction
Dronedarone is an antiarrhythmic medication used 
for the treatment of atrial fibrillation (AF) and atrial 
flutter (AFL) and in the reduction of cardiovascular 
hospitalizations in high risk AF patients. This paper 
reviews  the  clinical  pharmacology,  electrophysiol-
ogy, clinical trial data, efficacy and adverse effects of 
this new antiarrhythmic agent.
Electrophysiological Properties
Dronedarone is a non-iodinated benzofuran derivative 
of amiodarone with similar multichannel blocking elec-
trophysiologic properties1–22 (Fig. 1). Like amiodarone, 
it has Class III effects, inhibiting the potassium cur-
rents IKr, IKs, IK1, and IKAch and does not have reverse 
use-dependence.12,13 Dronedarone is a 100 times more 
potent inhibitor than amiodarone in blocking the IKAch 
channel.16 Similar to amiodarone, dronedarone demon-
strates use-dependent block of the maximum upstroke 
velocity  (Vmax)  of  the  papillary  muscle,12  suggesting 
block of the fast inward INa. In vitro studies showed 
that  concentration  of  dronedarone  to  produce  inhi-
bition  equivalent  to  amiodarone  was  approximately 
10  fold  lower.21  Under  whole-cell  patch  clamp  on 
human  atrial  myocytes,  amiodarone  inhibited  INa  by 
only 41% at 3 µM while dronedarone inhibited INa by 
97% at 3 µM.21 Thus, in vitro studies demonstrate that 
the blocking effects of the two drugs on different chan-
nels are not equivalent. Dronedarone is a more potent 
inhibitor of slow L-type Ca channel (class IV   activity) 
when  compared  to  amiodarone,  with  the  inhibitory 
concentration  50%  of  dronedarone  being  50  times 
less than amiodarone.15 Dronedarone is an antagonist 
of α- and β-adrenoceptors and thus exhibits class II 
activity,20 but has less β1 adrenoreceptor antagonistic 
effect compared to amiodarone. In conscious dogs with 
healed  myocardial  infarction,  dronedarone  displayed 
antiadrenergic  actions  comparable  to  those  of  amio-
darone and both drugs reduced exercise-induced tachy-
cardia and decreased isoproterenol-induced tachycardia 
without impairing rest left ventricular function.23
Sustained administration of dronedarone increases 
the  QTc  interval  and  has  been  shown  to  exhibit 
less  reverse  use-dependency  of  repolarization  than 
  amiodarone.12  Similar  to  amiodarone,  dronedarone 
decreases the transmural dispersion of repolarization 
(TDR) by blocking both IKr and IKs and late sodium 
channels.22  By  blocking  late  INa,  dronedarone  has 
minimal effects on epicardial and endocardial action 
potentials but produces a marked effect on the action 
potential of M cells. The net effect is that dronedarone 
induces a small increase in action potential duration of 
endocardium and epicardium, with little effect in the 
M cells and homogenizes the transmural dispersion in 
refractoriness. The risk of proarrhythmia is further low-
ered by inhibiting slow L-type Ca channel, the mini-
mal effect on reverse use-dependence and significantly 
reducing early after depolarization (EAD) and delayed 
after depolarization (DAD) induced by dofetilide and 
strophantidine in dog Purkinje fibers.22 The above basic 
electrophysiology of dronedarone predicts a low risk 
of dronedarone-induced torsade de pointes.
The  net  electrocardiographic  manifestations 
of  dronedarone  effect  include  sinus  rate  slowing,   
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Figure 1. Chemical structure of amiodarone and dronedarone (reproduced with permission).2Dronedarone for atrial fibrillation/flutter
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PR  prolongation  and  mild  QTc  prolongation  with 
little effect on QRS duration.
Basic  studies  have  demonstrated  that  drone-
darone  can  suppress  ischemia-induced  ventricular 
arrhythmias.24–26 In a rat model of ischemia, drone-
darone  significantly  reduced  the  incidence  of  ven-
tricular fibrillation from 80% to 30% (P , 0.05) at 
3 mg/kg and eliminated ventricular fibrillation and 
mortality at 10 mg/kg.24 On reperfusion, dronedarone 
reduced  the  incidence  of  mortality  (from  90%  to 
20%, P , 0.01) at 1 mg/kg and eliminated ventricular 
fibrillation and mortality when administered at 3 and 
10  mg/kg.  In  anesthetized  pigs,  dronedarone  was 
more potent than amiodarone in reducing ischemia-
induced ventricular arrhythmias.26
pharmacokinetics and metabolism  
of dronedarone
Dronedarone  is  N-[2-butyl-3[4-(3-dibutylamino-
propoxy)benzoyl]-benzofurane-5-yl] methanesulfon-
amide hydrochloride. Dronedarone differs structurally 
from amiodarone in that the iodine moiety has been 
removed and a methane-sulfonyl group has been added 
(Fig. 1). These modifications were made in an effort 
to reduce the thyroid and other end-organ adverse 
effects associated with amiodarone. The addition of 
the methane-sulfonyl group makes dronedarone less 
lipophilic, greatly shortening its half-life.1,2
After  oral  administration,  approximately  70% 
to  94%  of  dronedarone  is  absorbed  and  absorp-
tion  increases  2–3  fold  when  it  is  taken  with  food 
(  especially  high  fat).  Dronedarone’s  bioavailability 
is  relatively  low  (about  15%)  because  of  extensive 
hepatic  first-pass  metabolism  by  cytochrome  P450 
CYP3A4  and  CYP2D6,  thus  requiring  twice-daily 
dosing  to  achieve  steady-state  serum  levels.27  Only 
6% of dronedarone is excreted via a renal route and it 
does cross the   blood-brain barrier or the placenta and 
is excreted into breast milk. Dronedarone and its active 
N-debutyl metabolite are highly protein bound and the 
volume of distribution of dronedarone is 1200–1400 L. 
Steady state plasma concentrations of 84–167 ng/mL 
are reached in 7 days and the terminal elimination half-
life of the drug varies from 13 to 31 hours.5 Based on 
data from trials, the only recommended dose is 400 mg 
twice daily with meals and no dose adjustment has been 
proposed for age, gender, race, or renal function.
Dronedarone, similar to amiodarone, partial inhibits 
the tubular transport of creatinine, resulting in slightly 
increased  (10%–20%)  creatinine  levels.28  However, 
dronedarone has no meaningful effect on renal func-
tion as measured by the glomerular filtration rate.
Drug-interactions
Drugs that interact with dronedarone and interaction 
mechanisms are summarized in Table 1. Dronedarone 
is highly metabolized by CYP3A4 and dronedarone is 
a moderate inhibitor of CYP3A4 and a weak inhibi-
tor  of  CYP2D6.  Dronedarone  has  interactions  with 
other drugs using the CYP450 systems.5 Dronedarone 
should not be administered at the same time with potent 
CYP3A4 inhibitors including antifungals, macrolide 
antibiotics and protease inhibitors, since CYP3A4 inhi-
bition may increase plasma levels of dronedarone and 
cause unwanted adverse effects. Dronedarone can be 
coadministered  with  moderate  CYP3A4  inhibitors 
such as verapamil and diltiazem, but with some cau-
tion including using lower doses of these drugs.
Similar  to  amiodarone,  dronedarone  is  a 
P-  glycoprotein inhibitor and can increase the level of 
digoxin and   dabigatran if co-administered together 
(Table 2). Since digoxin levels can double, digoxin 
doses should be cut in half if dronedarone is added 
to  avoid  digitalis  toxicity.29  Dabigatran  levels  can 
Table 1. Cardiovascular drug interactions with dronedarone.*
Drug Mechanism Effect Dose adjustment
Digoxin p-g p substrate 2.5-fold increase digoxin level Halve the digoxin dose
verapamil, 
diltiazem
CYp3A inhibitors 1.4 to 1.7 fold increase 
in dronedarone level
Lower dose of calcium channel  
blocker dose
β blockers CYp2D6 substrate 1.6 fold increase in metoprolol level Lower β blocker dose
Simvastatin CYp3A substrate Up to 4-fold increase in simvastin level Maximum simvastatin dose 10–40 mg
Dabigatran p-g p Substrate 1.1-1.9 increase in dabigatran level Consider lower dose of dabigatran
Note: *Modified from reference 7.
Abbreviations: p-g p, p-glycoprotein; CYp, cytochrome.Naccarelli et al
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Table 2. Similarities and differences between amiodarone and dronedarone.*
Amiodarone Dronedarone
Iodine moiety Yes No
Elimination half life 53 days 14–30 hours
Lipophilic properties Strong Moderate
Tissue accumulation Yes No
Blocks IKr; IKs; B1; ICa; Ito; INa Yes Yes
Dosing Daily after loading Twice daily with meals
Food effect Yes Yes
CYp4503A4 metabolism Yes Yes
Increases creatinine Yes Yes
Increase QT but low TDp Yes Yes
Efficacy in suppressing AF 65% 50%
rate control in AF Yes Yes
Efficacy in suppressing ventricular tachyarrhythmias Yes probably
Decreases Cv hospitalization No Yes
warfarin interaction Yes No
Dabigatran interaction Yes Yes
Digoxin interaction Yes Yes
Simvastatin interaction Yes Yes
pulmonary/thyroid toxicity Yes No
Hepatic toxicity Yes Yes
Safety concerns in CHF SCD-HeFT (NYHA III) ANDrOMEDA
Note: *Modified from references 7, 45.
Abbreviations: TDP, torsade de pointes; AF, atrial fibrillation; CV, cardiovascular; CHF, congestive heart failure.
increase up to 1.9 times but currently no dose adjust-
ment is recommended, although some clinicians have 
recommended taking the drugs 2 hours out of phase 
with each other in an attempt to avoid a peak to peak 
drug interaction.
Warfarin is a mixture of the S enantiomer, which 
is  approximately  3  times  more  potent  than  the 
Renantiomer, and is metabolized primarily by CYP2C9. 
Inhibition of CYP2C9 by amiodarone and desethyl-
amiodarone  potentiates  the  anticoagulant  effects  of 
warfarin,  increasing  the  risk  of  serious  bleeding. 
Dronedarone does not significantly inhibit CYP2C9 
and  thus  does  not  have  clinically  significant  inter-
action with warfarin (Table 2). In healthy subjects, 
dronedarone at a dose of 600 mg twice daily increased 
S-warfarin exposure by 1.2-fold with no change in 
R-warfarin and with no clinically significant increase in 
INR.30 In clinical trials in patients with AF/AFL, there 
was no observed excess risk of bleeding compared to 
placebo when dronedarone was co-  administered with 
oral anticoagulants.   DIONYSOS was the only trial 
that performed a head-to-head   comparison between 
dronedarone  and  amiodarone.31  In  the  dronedarone 
arm, the risk of hemorrhagic events was approximately 
50% lower (HR = 0.504 [0.266–0.954]). There were 
14 of 249 hemorrhagic events in the dronedarone group 
and 29 of 255 in the amiodarone group (P = 0.03). The 
incidence of lower hemoglobin level values was 4.7% 
in amiodarone arm as compared to 1.3% in the drone-
darone arm. The amiodarone group also required more 
frequent downward adjustments in warfarin dose from 
day 5 to the end of study period. At day 10, doses of 
anticoagulants were decreased for approximately 48% 
of patients in the amiodarone group as compared to 
20%  in  the  dronedarone  group.  Patients  with  INR 
values  greater  than  4.5  were  more  common  in  the 
amiodarone group. At day 10, approximately 25% of 
patients in amiodarone group had INR values greater 
than 4.5 as compared to 9% in the dronedarone group. 
One intracranial hemorrhage was reported in the ami-
odarone group versus none in the dronedarone group. 
Since market release, anecdotal increases in INR have 
been reported in patients taking dronedarone, so close 
monitoring of INR levels is still recommended.
Dronedarone  also  interacts  with  commonly  pre-
scribed  drugs  such  as  metoprolol  and  simvastatin 
(Table 1). Dronedarone can increase serum   simvastatin 
levels  2  to  4  fold  and  thus  promote  statin-induced 
  myalgia.  Recently,  it  has  been  recommended  that 
  simvastatin  doses  should  be  low  (10  mg  a  day)  in   Dronedarone for atrial fibrillation/flutter
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patients  taking  simvastatin  in  combination  with 
  amiodarone. No specific recommendation was made 
for the use of simvastatin with dronedarone. We recom-
mend using simvastatin doses no higher than 10–40 mg 
a  day  when  used  in  conjunction  with  dronedarone. 
Since dronedarone interactions with atorvastatin and 
rosuvastatin are less marked and there is no significant 
interaction with pravastatin, these lipid lowering agents 
are safer to use in combination with dronedarone.
Metoprolol  and  dronedarone  interact  via-
CYP2D6 inhibition that results in an increased bio-
availability of metoprolol.32
Clinical Trials
The  initial  dronedarone  trials  including  DAFNE,33 
EURIDIS/ADONIS,34 and ERATO35 were designed to help 
establish efficacy, dosage and rate control (Table 3).
DAFNE (dronedarone atrial fibrillation 
study after electrical cardioversion)33
In DAFNE, doses of 400 mg, 600 mg or 800 mg 
were given twice a day. This study included patients 
with long-standing persistent AF (82–122 days) who 
were  randomized  to  the  stated  doses  or  placebo. 
Patients were electrically converted if they were still 
in AF 5–7 days after initiation of medication. The 
primary outcome was time to first documented AF 
recurrence, defined as an episode lasting for at least 
10 min and documented by two distinct ECGs sepa-
rated by the same time duration. Only with 800 mg/day 
of dronedarone was the time to first AF recurrence 
statistically (P , 0.05) prolonged from 5.3 days in 
the placebo group to 56.6 days in dronedarone group. 
The two higher dose dronedarone groups (1200 and 
1600 mg/day) demonstrated no significant change in 
the time to first recurrence of AF, indicating a lack 
of dose effect. Another important finding of this trial 
was the poor medical conversion rate of dronedarone: 
which ranged from 5.8% with 800 mg/day dose to 
14.8% with the maximum 1600 mg/d.
The main adverse effects were gastrointestinal in 
nature (nausea and diarrhea) and these side effects 
were dose-dependent. The lowest dose (400 mg twice 
daily with meals) was found to have the best efficacy, 
and was better tolerated with less gastrointestinal side 
effects. Based on this finding, future trials were all 
planned with 400 mg twice daily with meals. Very 
little dose ranging information is otherwise   available 
and  lower  doses  of  dronedarone  have  not  been 
  well-studied.
EUrIDIS (The European trial in atrial 
fibrillation or flutter patients receiving 
dronedarone for the maintenance of sinus 
rhythm) and ADONIS (the American-
Australian-African trial with   dronedarone 
in atrial fibrillation or flutter patients for the 
maintenance of sinus rhythm) trials34
Based on the results of DAFNE, dronedarone was 
400 mg twice a day was used in EURIDIS (European 
trial)  and  ADONIS  (American-Australian-African 
trial). These two identical trials involved patients with 
paroxysmal and persistent AF (underwent successful 
electrical cardioversion and remained in sinus rhythm 
for at least 1 hour). Previous treatment with amio-
darone was permitted, and patients could be enrolled 
within  48  hours  of  amiodarone    discontinuation. 
Important  exclusion  criteria  were  permanent  AF, 
bradycardia  less  than  50  BPM,  history  of  torsade 
de pointes, PR greater than 0.28s, second degree or 
higher AV block, CHF NYHA class III or IV, crea-
tinine level of 1.7 mg per deciliter or greater. The 
total number of patients included in both trials was 
1237, with 828 treated with dronedarone therapy due 
to a 2:1 dosing regimen with placebo. For the two 
trials combined, the median times to a documented 
recurrence of AF was 116 days in the dronedarone 
group and 53 days in the placebo group (P , 0.05). 
At 12 months, the maintenance of sinus rhythm with 
dronedarone was modest with rates of recurrence of 
64.1% in the dronedarone group and 75.2% in the 
placebo group (P , 0.001). When compared to pla-
cebo, there was evidence of a rate controlling effect of 
dronedarone of 14 bpm in cases where AF recurred.
Hyperthyroidism occurred more frequently in the 
placebo group (14.1%) than the dronedarone group 
(8.4%) (P , 0.002). Mild QT and QTc prolonga-
tion (23 and 9 ms respectively) was noted but there 
were no reported episodes of torsade de pointes in 
the dronedarone treated patients. No end organ tox-
icity was reported including a similar incidence of 
elevated liver function tests in the dronedarone and 
placebo arms of the study.
ADONIS/EURIDIS  demonstrated  a  significant 
increase in the median time to first recurrence of AF, Naccarelli et al
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and  a  decrease  in  the  ventricular  response  during 
AF recurrences. In addition, a retrospective analysis 
suggested that dronedarone decreased the   composite 
  endpoint  of  death  and/or  cardiovascular  hospital-
ization.34 ADONIS/SEURIDIS demonstrated that 
dronedarone  statistically  reduced  the  frequency  of 
AF compared to placebo although the magnitude of 
effect was only about 25%. Although the magnitude 
of effect was significant, it did not appear to be as 
high as one would expect with amiodarone.
Efficacy and safety of dronedarone  
for control of ventricular rate (ErATO) 
trial further established dronedarone’s 
effectiveness in rate control of 
permanent atrial fibrillation35
The primary objective of ERATO was to assess the 
efficacy of dronedarone in the control of mean 24-hour 
  ventricular rate in patients with permanent AF on day 14. 
Secondary  objectives  included  assessment  of  the 
effects of dronedarone on heart rate during exercise, 
the impact of treatment on exercise tolerance, mean 
24-hour ventricular rate at 4 months and the tolerability 
of dronedarone. Dronedarone reduced mean 24 hours 
ventricular rate by 11 BPM on day 14 compare to day 0 
as opposed to increase by 0.7 BPM in placebo group. 
The prespecified subgroup analysis by concomitant 
rate-lowering  medication  revealed  that  HR  was,  in 
addition, lowered by dronedarone in patients receiv-
ing β-blocker, digoxin and calcium channel-blocker, 
with mean reductions in ventricular rate versus pla-
cebo of -14.9, -11.5, and -5.1 beat/min respectively. 
The least reduction of ventricular rate was in patients 
pretreated with calcium channel blockers.
At maximal exercise, there was a reduction in mean 
heart rate of 27.4 beat/min in the dronedarone group, 
compared  with  2.9  beat/min  in  the  placebo  group 
(P , 0.0001) a treatment effect of 24.5 beat/min. The 
decrease in HR with dronedarone observed at day 14 
was sustained during long-term treatment at 4 months.
ANDrOMEDA (antiarrhythmic trial with 
dronedarone in moderate to severe CHF 
evaluating morbidity decrease study)36
ANDROMEDA included systolic dysfunction patients 
(wall motion index 1.2 or less (approximating an ejec-
tion  fraction  of  no  more  than  35%)  with  advanced 
CHF NYHA class III or IV or a heart failure related 
hospitalization) within 1 month before randomization. 
Enrollment and study treatment was prematurely dis-
continued for safety reasons on the recommendation 
of the data and safety monitoring board because of an 
increased number of deaths among patients who were 
assigned to dronedarone therapy (n = 25) as compared 
with those assigned to placebo (n = 12). Worsening heart 
failure was 5 times higher in dronedarone group than 
placebo, 10 pts (3.2%) and 2 pts (0.6%)   respectively. 
The most powerful predictor of death was treatment 
with dronedarone. After an additional 6 months with-
out study treatment, number of death was not statis-
tically significant between the groups: 42 patients in 
the dronedarone group (13.5%) and 39 patients in the 
placebo group (12.3%) had died (P = 0.60).
Several  explanations  were  proposed  to  explain 
study results. One explanation proposed by sponsor 
of the trial was withdrawal of ACE-I/ARBs. Detailed 
discussion of this hypothesis is beyond the scope of cur-
rent review but increased mortality in   ANDROMEDA 
trial  cannot  be  attributed  to  inappropriate  discon-
tinuation of ACE-I or ARBs. In the placebo group, 
50 patients were never on ACE-I or ARB and only 
1 died (2%) versus in the dronedarone group 6 out 
of 16 patients naïve to ACE-I or ARB died (6%). An 
alternative explanation of the above results includes 
a chance effect in an under-powered study. The most 
likely explanation of ANDROMEDA is the negative 
inotropic effect of dronedarone lead to worsening of 
heart failure.37 Dronedarone is strong INa and ICa chan-
nel inhibitor and the drug may have a stronger nega-
tive inotropic effect than amiodarone.
ATHENA (a placebo-controlled, 
double-blind, parallel arm trial to assess 
the efficacy of dronedarone 400 mg 
bid for the prevention of cardiovascular 
hospitalization or death from any  
cause in patients with atrial  
fibrillation/atrial flutter)38
ATHENA was the largest antiarrhythmic drug trial 
(4628 patients) ever performed with an antiarrhyth-
mic agent in AF/AFl. It was designed, in response to 
ANDROMEDA, to determine whether dronedarone 
would reduce the composite outcome of hospitaliza-
tion due to cardiovascular events or death in patients Naccarelli et al
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with AF. ATHENA was performed to focus on patients 
at risk of AF recurrence who may or may not have had 
heart failure, but would not have been randomized in 
the ANDROMEDA trial. Thus, key exclusion criteria 
for ATHENA was pulmonary edema within 12 hours, 
cardiogenic  shock  requiring  intravenous  pressors 
and/or mechanical ventilation or Class IV heart fail-
ure  within  4  weeks. ATHENA  was  performed  for 
several other regulatory reasons: (1) to verify the post-
hoc result from ADONIS/EURIDIS that dronedarone 
prospectively could reduce the composite endpoint of 
cardiovascular hospitalizations/death; (2) to create a 
large database to show that dronedarone would be 
safe in a broad number of patients with structural 
heart  disease;  and,  (3)  to  define  a  point  estimate 
to show that this drug could be used safely in high 
risk AF/AFL patients excluding the ANDROMEDA 
  population. Inclusion criteria included: The majority 
of the patients enrolled in ATHENA had normal or 
low normal EF and an EF of less than 45% was only 
present in 11.3% of the patients in dronedarone group 
and 12.5% in placebo group. A history of CHF, NYHA 
class II or III was present only in 20% in dronedarone 
group and 22% in placebo.
ATHENA demonstrated a statistical reduction in 
all-cause mortality or cardiovascular hospitalization 
in the dronedarone group. The hazard ratio was 0.76 
(0.69–0.84; P , 0.001). Treatment with dronedarone 
results in one fewer death or cardiovascular hospital-
ization for every 12 patients treated for 21 months. 
Even though dronedarone did not significantly reduce 
mortality [HR = 0.84 (CI 0.66–1.08)], cardiovascular 
death, sudden cardiac death, and death from stroke 
were all significantly reduced (Fig. 2). This finding 
was necessary for regulatory approval. The FDA man-
dates that drugs show a hazard ratio of less than 1.50 
for any potential increase in mortality. There is mini-
mal  overlap  of  the  mortality  confidence  intervals 
in the two trials with different patient populations. 
Thus, ATHENA properly excluded ANDROMEDA-
like patients and dronedarone could safely be used in 
ATHENA-like  patients.  Sub-analyses  of  ATHENA 
showed favorable reductions of the primary endpoint 
in patients of NYHA III class, with ejection fractions 
of less than 35%, and also in those receiving   diuretics, 
beta-blockers  or  ACE  inhibitors.  This  dichotomy 
is highlighted in dronedarone’s package insert that 
includes a box warning that contraindicates the use of 
dronedarone in ANDROMEDA-like patients.39
The primary outcome (the first hospitalization due 
to cardiovascular events or death from any cause) was 
strongly positive in favor of dronedarone (P , 0.001) 
but was driven heavily by the decrease in the num-
ber  of  first  hospitalizations  due  to  cardiovascular 
events, which was driven mainly by a reduction in 
the number of hospitalizations for AF (Fig. 3). There 
were also significantly fewer hospitalizations for an 
acute coronary syndrome in the dronedarone arm of 
the study. Death from any cause, one of the prespeci-
fied  secondary  endpoints,  was  less  in  dronedarone 
Placebo
n = 2327
Dronedarone
n = 2301 HR p value
0.18 0.66; 1.08 0.84 116 139 All death
Non-CV death
0.03 0.51; 0.98 0.71 63 90 CV death
Cardiac non-arrhythmic
death
18
Cardiac arrhythmic
death
48
Vascular non-cardiac 24
95% CI
0.89 0.49; 1.85 0.95 17
0.01 0.34; 0.88 0.55 26
0.57 0.47; 1.52 0.84 20
0.65 0.74; 1.62 1.10 53 49
Figure 2. Death, non-cardiovascular and cardiovascular death rates in ATHENA.45 
Abbreviation: ACS, acute coronary syndrome.Dronedarone for atrial fibrillation/flutter
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group than placebo (116 pts or 5% vs. 139% or 6%, 
P = 0.18). Cardiovascular death, other prespecified 
secondary endpoint, reached statistical significance 
in favor of dronedarone with absolute reduction only 
1.2% (3.9% vs. 2.7% in placebo versus dronedarone 
group respectively). Further analysis of cardiovascular 
causes of death showed that dronedarone reduced sud-
den cardiac death, with a relative reduction 45% (2.1% 
in placebo group and 1.1% in dronedarone group), 
suggesting  a  therapeutic  effect  of    dronedarone  in 
suppressing ventricular arrhythmias.
A post hoc analysis of the ATHENA data was done 
to investigate the effect of dronedarone on stroke risk 
in this population.40 This analysis demonstrated that 
dronedarone reduced the risk of stroke from 1.8% per 
year to 1.2% per year (hazard ratio 0.66, 95% confi-
dence interval 0.46 to 0.96, P = 0.027) (Fig. 4). The 
effect  of  dronedarone  was  similar,  whether  or  not 
Reason for first CV 
hospitalization
Placebo
n = 2327
Dronedarone
n = 2301 HR p value
<0.001 0.67; 0.82 0.74 675 859 Any reason
Atrial Fibrillation 510
CHF 132
ACS 89
Syncope 32
Ventricular arrhythmia or 
cardiac arrest
12
95% CI
<0.001 0.55; 0.72 0.63 335
0.22 0.67; 1.10 0.86 112
0.03 0.51; 0.97 0.70 62
0.54 0.51; 1.42 0.85 27
0.83 0.50; 2.39 1.09 13
Figure 3. Cardiovascular hospitalization rates in ATHENA.45 
Abbreviations: ACS, acute coronary syndrome; Cv, cardiovascular; CHF, congestive heart failure.
Placebo Dronedarone
HR 95% CI p
# Events Rate/Yr#  Events Rate/Yr
Stroke 70 1.79%4 61 .19% 0.66 0.46−0.960 .027
Stroke-related
hospitalizations 55 1.4%3 8 1.0% 0.69 0.46−1.05 0.082
Ischemic stroke 49 1.3%3 3 0.9% 0.68 0.44−1.05 0.081
Hemorrhagic
stroke 60 .2%50.1% 1.01 0.33−3.13 0.987
Stroke or TIA 80 2.05%5 31 .37% 0.67 0.47−0.940 .020
Fatal stroke 21 0.54%1 40 .36% 0.67 0.34−1.320 .247
Stroke, ACS or
CV Death 216 5.52%1 47 3.80% 0.68 0.55−0.84 <0.001
Stroke, ACS or
Death 262 6.70%1 96 5.06% 0.75 0.62−0.90 0.002
Figure 4. Effect of dronedarone on stroke endpoints in ATHENA.45 
Abbreviations: ACS, acute coronary syndrome; Cv, cardiovascular; TIA, transient ischemic attack.Naccarelli et al
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patients were receiving oral anticoagulant therapy, and 
there was a significantly greater effect of dronedarone 
in patients with higher CHADS2 scores. In addition, 
there was a 31% reduction in stroke-related hospi-
talizations, a 32% reduction in ischemic stroke, and 
no difference in hemorrhagic stroke. Composites of 
stroke including stroke, acute coronary syndrome or 
cardiovascular death were also statistically reduced by 
dronedarone. Although the numbers were small, there 
were only 2 strokes in the permanent atrial fibrillation/
atrial flutter population on dronedarone compared to 
8 events in patients treated with placebo, who also had 
permanent atrial fibrillation. The decreased stroke risk 
in the dronedarone treated group of the ATHENA trial 
could be attributed to reduction of atrial fibrillation 
frequency. Dronedarone’s modest reduction in blood 
pressure, and more substantial decrease in heart rate 
during atrial fibrillation are other potential mecha-
nisms of decreased stroke risk.41,42 The PALLAS trial, 
included composite stroke endpoints that were statis-
tically worse on dronedarone therapy. The results of 
PALLAS raise the question of any stroke reduction 
benefit with dronedarone, although the populations 
studied were different.
ATHENA  was  a  large  safety  trial  designed  to 
test whether dronedarone could be used in patients 
with  atrial  fibrillation  and  structural  heart  disease. 
The study enrolled patients with either persistent or 
  paroxysmal AF and at least one cardiovascular risk 
factor. The same dose (400 mg twice a day) was used 
in  this  study  as  in  ANDROMEDA.  Patients  with 
Class IV or recently decompensated heart failure were 
excluded. The results of ATHENA were significant 
reductions in the primary end points of all-cause mor-
tality and cardiovascular hospitalization. The   hazard 
ratio  for  the  primary  outcome  in  the  dronedarone 
group was 0.76. The reduced rate of hospitalizations 
due to cardiovascular events was mainly attributed to 
fewer admissions for atrial fibrillation. In the drone-
darone treated group the only significant adverse side 
effects were nausea, diarrhea, bradycardia, rash and 
QT prolongation. The rates of thyroid and pulmonary 
adverse events were no different from placebo.
Post-ATHENA
In ATHENA, dronedarone reduced the primary end-
point of cardiovascular hospitalization [HR = 0.75 
(CI 0.67–0.82)] although dronedarone had no effect 
on reducing hospitalizations for non-cardiovascular 
reasons [HR = 0.98 (CI 0.87–1.11)]. Although there 
was a decrease in cardiovascular hospitalization by 
suppression of AF and other supraventricular disor-
ders [HR = 0.62 (CI 0.53–0.71)], the time to first car-
diovascular hospitalization not due to AF/AFL was 
also increased [HR = 0.85  (CI  0.75–0.97)]. Thus, 
although AF admissions were reduced by 37% (HR 
0.63; P , 0.001), a significant reduction in cardio-
vascular hospital admissions were secondary to non-
arrhythmic causes; as an example, acute coronary 
syndrome admissions were decreased by 30% (HR 
0.70; P = 0.03) (Fig. 3). Dronedarone also signifi-
cantly decreased the risk of unplanned cardiovascu-
lar hospitalization and death from any cause by 24% 
(hazard ratio (HR) 0.76; P , 0.001) and decreased 
total unplanned cardiovascular hospitalization days 
by 28% (P , 0.001). This resulted in a 35% reduc-
tion (P , 0.001) in the total length of time spent in 
the hospital for cardiovascular reasons, including a 
statistical  reduction  of  critical  care,  medium  care, 
and ward days in hospital.43 Another post-hoc anal-
ysis of ATHENA demonstrated a similar benefit in 
patients with lone AF.44 Naccarelli et al reported that 
healthcare costs associated with CV hospitalizations 
and in patient deaths among ATHENA-like patients 
in the United States are high, with a mean of $10,908 
per  nonfatal  admission.45  Over  a  one  year  period, 
these 53.9% of these patients had a cardiovascular 
hospitalization. Thus a reduction in cardiovascular 
hospitalization in this population, by therapies such 
as dronedarone, would be expected to reduce health 
care costs.46
A  post-hoc  analysis  of  ATHENA  demonstrated 
that dronedarone decreased unplanned cardiovascu-
lar hospitalization or death in permanent AF patients 
by 26% (HR = 0.74; P = 0.096).47 The mechanism for 
this reduction might be secondary to the added rate 
control properties of dronedarone (mean ventricular 
response was 9 bpm lower, P , 0.001) or some other 
unknown mechanism. A large prospective randomized 
trial (PALLAS) is randomized permanent AF patients 
to dronedarone versus placebo. The co-primary end-
points of this study include the composite endpoint 
of  stroke,  systemic  arterial  embolism,  myocardial 
infarction or cardiovascular death and a second com-
posite endpoint of first unplanned cardiovascular hos-
pitalization or death from any cause. This trial was Dronedarone for atrial fibrillation/flutter
Clinical Medicine Insights: Cardiology 2011:5  113
prematurely terminated due to adverse effects in the 
dronedarone arm of the study.
Although there has been concern in using drone-
darone in patients with congestive heart failure, post-
hoc analyses from the ATHENA trial48 demonstrated 
a 22% reduction in cardiovascular hospitalization or 
death (HR = 0.78) in a small cohort of 209 patients 
with New York Heart II/III congestive heart failure 
and  a  left  ventricular  injection  fraction  of  #40% 
at baseline. There was no difference between these 
209 patients and the 4,335 patients without a history 
of heart failure or depressed ejection fraction who 
had a hazard ratio of 0.76 for unplanned cardiovascu-
lar hospitalization or death.
DIONYSOS (efficacy and safety  
of dronedarone versus amiodarone  
for the maintenance of sinus rhythm  
in patients with atrial fibrillation)31
DIONYSOS  recruited  504  patients  with  persistent 
AF over a median follow-up period of 7 months. The 
main exclusion criteria were previous chronic treat-
ment with amiodarone, hypo- or hyperthyroidism, or 
other contraindications to amiodarone, (corrected QT 
(QTc)-interval $500 ms, paroxysmal AF/atrial flut-
ter, New York Heart Association (NYHA) class III 
or IV congestive heart failure, severe bradycardia, or 
high-degree atrioventricular block.
The primary composite endpoint of the study was 
a measurement of efficacy, defined as recurrence of 
AF or premature study drug discontinuation for lack 
of efficacy. The main safety endpoint was the occur-
rence  of  adverse  effects  or  premature  study  drug 
discontinuation following an adverse event. The inci-
dence of the composite primary endpoint was 75.1% 
and 58.8% in the dronedarone and amiodarone groups, 
respectively, at 12 months   treatment. The composite 
primary endpoint was mainly driven by the AF recur-
rence  component  which  was  more  frequent  in  the 
dronedarone group  compared with the amiodarone 
group  (63.5%  vs.  42.0%),  while  the  premature 
drug  discontinuation  component  was  less  frequent 
(10.4%  vs.  13.3%,  respectively).  Fewer  patients 
treated with dronedarone had spontaneous conversion 
(29 versus 83). In addition, the recurrence rate after 
conversion to sinus rhythm was 36.5% in the drone-
darone group and 24.3% in the amiodarone group 
and accounted for the majority of AF   recurrences. 
The  incidence  of  the  meaningful  side  effects  was 
39.3% and 44.5% in the dronedarone and amiodarone 
groups,  respectively.  The  dronedarone  group  had 
fewer thyroid, neurologic, skin, and ocular events but 
more gastrointestinal events, mainly diarrhea.
The DIONYSOS trial31 showed that amiodarone 
was  more  effective  in  reducing  atrial  fibrillation 
recurrences  post-cardioversion  compared  drone-
darone.  The  dronedarone  group  tended  to  have  a 
lower frequency of adverse events specifically less 
problems  with  thyroid  disorders  or  bleeding  from 
any   warfarin interaction compared to amiodarone. In 
addition, a post hoc analysis of DIONYSOS demon-
strated that dronedarone had a more favorable effect 
in reducing cardiovascular hospitalizations and death 
compared to the amiodarone limb of the study. This 
dichotomy in amiodarone having more effective anti-
arrhythmic  properties  for  atrial  fibrillation  yet  not 
having the same endpoint value compared to drone-
darone probably relates to a combination of improved 
safety with dronedarone and some other properties, 
such as blood pressure lowering.49 In the rhythm con-
trol arm of both AFFIRM and AF-CHF, with 62% 
and  82%  amiodarone  use  respectively,  there  were 
statistically  higher  rates  of  cardiovascular  hospi-
talizations50–53 ( Fig.  5).  The  high  re-hospitalization 
rates were   counter-intuitive given amiodarone’s effi-
cacy in suppressing AF recurrences. To highlight this 
dichotomy, in DIONYSOS, amiodarone was superior 
to dronedarone in preventing AF recurrences, but in 
AFFIRM and AF-CHF, amiodarone was ineffective 
in reducing mortality and actually increased cardio-
vascular   hospitalizations. However, in DIONYSOS, 
dronedarone was statistically inferior to amiodarone 
in AF prevention, but had a favorable effect on reduc-
ing cardiovascular hospitalizations in ATHENA.
Dronedarone: antiarrhythmic efficacy 
and differences from amiodarone
Dronedarone  is  not  as  effective  an  antiarrhythmic 
drug in suppressing AF as amiodarone.31 Some have 
suggested that dronedarone is not an effective anti-
arrhythmic  agent.54  However,  dronedarone  showed 
statistically  beneficial  antiarrhythmic  effects  com-
pared to placebo in ADONIS/EURIDIS.34 In post-hoc 
analyses of ATHENA,55 dronedarone reduced a time 
to first cardioversion by 31% (P , 0.001), the time to Naccarelli et al
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first AF/AFl occurrence by 25% (P , 0.001), reduced 
the number of patients in permanent AF from 12.8% 
in  placebo  to  7.7%  in  dronedarone  (P  ,  0.001). 
  Several studies have demonstrated that dronedarone 
is less effective than amiodarone in preventing AF 
but safer and as effective as other commercially avail-
able membrane active antiarrhythmic agents in main-
taining sinus rhythm56–58 (Fig. 6). In a meta-analysis, 
dronedarone was less effective than amiodarone for 
the maintenance of sinus rhythm, but was associated 
with  fewer  adverse  side  effects  necessitating  dis-
continuation of the drug.56 Additionally, there was a 
trend  toward  greater  all-cause  mortality  associated 
with amiodarone use. In dronedarone treated patients, 
the incidence of end organ toxicity, or symptomatic 
  bradycardia resulting in termination of the drug, was 
not  statistically  different  from  the  placebo  group. 
However, the incidence of pulmonary and liver toxic-
ity in the amiodarone users requiring drug discontinu-
ation was also no different from placebo. Basic studies 
demonstrate  that  dronedarone  is  less  effective  than 
amiodarone is suppressing AF59 but the addition of 
ranolazine to dronedarone added significant efficacy 
to either drug alone.60   Further studies of this combina-
tion may lead to a safe, effective combination antiar-
rhythmic agent.
Although  dronedarone  and  amiodarone  are  both 
multichannel blockers with low-proarrhythmic   profiles 
ATHENA AF-CHF AFFIRM
None 82% of patients 63% of patients Amiodarone use
P < 0.001 P = 0.001 P < 0.001 Hospitalization
P = 0.03 N/A CV mortality
P = 0.027 Stroke
Total mortality
Figure 5. Cardiovascular outcomes in ATHENA versus AFFIrM, AF-CHF.45
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there are significant differences between the two drugs5,6 
(Table 2). Dronedarone has no iodine moiety and thus 
would  not  affect  thyroid  metabolism.    Dronedarone 
has a shorter half life of 13–30 hours with no tis-
sue accumulation. Dronedarone has coronary vaso-
dilatation refractory to inhibition of the NO synthase 
pathway while amiodarone has coronary vasodilata-
tion highly dependent on this pathway.42 Dronedarone 
has a greater antihypertensive effect and no end organ 
toxicity or warfarin interaction. In addition it is impor-
tant that dronedarone poses a different electrophysi-
ologic  profile  to  amiodarone. Although  both  drugs 
block inward sodium and calcium current and the out-
ward potassium currents including the atrial-selective 
currents there is a different magnitude of the channel 
blocking effects of these two drugs.
The pleiotropic effects of dronedarone might par-
tially be explained by its ability to decrease systolic 
and diastolic blood pressure by 2–3 mm of mercury 
Hg compared to placebo and amiodarone or through 
some other properties including heart rate   slowing, 
coronary vasodilatation or properties that have yet 
to  be  determined.  The  mechanisms  causing  this 
blood pressure lowering are not completely under-
stood.  If  blood  pressure  lowering  explains  some 
of the beneficial outcomes noted in ATHENA are 
speculative. Further studies into the mechanisms of 
action of dronedarone, in addition to its antiarrhyth-
mic properties, may give us insight into the pleiotro-
pic effects of this interesting multichannel blocking 
antiarrhythmic drug.
In ATHENA, cardiovascular mortality had a rel-
ative  risk  reduction  of  30%  with  an  absolute  risk 
reduction of 1.13%. If we combine the annualized 
morbidity and mortality, the relative risk reduction 
using dronedarone in these patients is 25% with an 
absolute risk reduction of 7.5%. This compares favor-
ably  with  other  preventative  trials  in  cardiology.45 
Future  studies  will  clarify  the  mechanisms  of  this 
beneficial effect.
Adverse effects
Although dronedarone has some potential for adverse 
effects, it appears to be safer than amiodarone. Since 
dronedarone was developed without any iodine moi-
eties, it does not cause thyroid toxicity and thyroid 
monitoring is not required. There have been some 
post-marketing  reports  of  interstitial  lung  disease 
and pneumonitis in dronedarone patients. Many of 
these  patients  had  prior  exposure  to  amiodarone. 
  Pulmonary toxicity secondary to dronedarone appears 
to be rare and no certain causal relationship has been 
identified.
The most common adverse reactions from drone-
darone appear to be gastrointestinal, including nau-
sea (5.3%) and diarrhea (9.7%). Side effects are dose 
dependent. A combination of data from four clinical 
trials reported that amiodarone was associated with 
a greater all-cause mortality (OR: 1.61; CI: 0.97 to 
2.68; P # 0.066) and greater overall adverse events 
requiring  drug  discontinuation  versus  dronedarone 
(OR: 1.81; CI: 1.33 to 2.46; P , 0.001).41
Dronedarone  slows  heart  rate  and  prolongs AV 
nodal  refractoriness  and  thus  can  increase  the  PR 
interval. Dronedarone cause very mild QTc prolon-
gation and in clinical trial was not associated with 
increased risk of torsade de pointes. Although drone-
darone prolongs the QT interval, the risk of torsades 
de pointes is low. There were no cases of torsades 
de  pointes  reported  in  the  DIONYSOS  trial  and 
only one case in the ATHENA trial (in a patient with 
long QT syndrome). Similar to amiodarone, the low 
risk of torsades de pointes allows outpatient initia-
tion of the drug. However, the risk of proarrhythmia 
could significantly increase in the setting of a QTc 
interval .500 ms, since such patients were excluded 
from the drug trials. Further studies, to define the 
safety of allowing such QT prolongation, are needed. 
Dronedarone should not be used in conjunction with 
other drugs that prolong the QT interval, and should 
be used cautiously with drugs known to interact with 
dronedarone. Periodic electrocardiograms are advised 
to monitor patients for a prolonged QT interval and 
bradycardia.  Patients  should  be  instructed  to  take 
dronedarone with food to increase absorption, and to 
avoid grapefruit juice.
Monitoring of liver function tests during controlled 
trials did not show any signal for hepatic   toxicity. 
However, 2 cases of severe hepatocellular liver injury 
(out of over 300,000 drug exposures), including acute 
liver failure requiring transplant, has been reported 
in patients treated with MULTAQ in the postmarket-
ing setting. Currently we are advising patients treated 
with dronedarone to report immediately symptoms 
suggesting  hepatic  injury  (such  as  anorexia,  nau-
sea,  vomiting,  fever,  malaise,  fatigue,  right  upper Naccarelli et al
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  quadrant pain, jaundice, dark urine, or itching). In the 
USA, we are obtaining baseline and periodic hepatic 
serum enzymes, especially during the first 6 months 
of treatment. It is not known whether routine peri-
odic monitoring of serum enzymes will prevent the 
development of severe liver injury. If hepatic injury 
is suspected, we recommend prompt discontinuation 
of dronedarone and a search for a cause of hepatic 
injury. We are not restarting dronedarone in patients 
without another explanation for the observed liver 
injury. Patients with severe baseline hepatic impair-
ment should not take dronedarone, since the drug is 
metabolized by the CYP450 system.
Although dronedarone was not found to be terato-
genic in animal studies, dronedarone was not stud-
ied in pregnant women and is contraindicated for use 
during pregnancy. Due to the increased mortality in 
dronedarone treated patients in the ANDROMEDA 
trial, there is a box warning in the package insert 
against the use of the drug in patients with NYHA 
Class IV heart failure, or Class II-III heart failure with 
a recent decompensation requiring hospitalization or 
referral to a heart failure specialist.39
Other potential indications  
for dronedarone
Amiodarone, in spite of being the most often pre-
scribed  medication  for  treatment  of  AF,  is  FDA 
approved only for therapy of ventricular arrhythmia. 
Dronedarone has been approved only for the treat-
ment of AF and AFL. Dronedarone’s electrophysi-
ological effects on the ventricular myocardium are 
described above. However, there is limited data sug-
gesting that dronedarone can be used for the treatment 
of  ventricular  arrhythmias.61  Animal  studies  have 
demonstrated  that  dronedarone  has  antiarrhythmic 
properties in the ventricle.24–26 In a post-  myocardial 
infarction  rat  model,  dronedarone  was  effective  in 
suppressing  ventricular  arrhythmias.62  In  anesthe-
tized rats, dronedarone at dose 10 mg/kg given intra-
venous completely suppressed incidence of VF and 
mortality  during  ischemic  period  and  completely 
suppressed  reperfusion  induced  arrhythmia.  In  a 
pig model of acute coronary occlusion dronedarone 
was more effect give than amiodarone, sotalol and 
lignocaine  in  preventing  ventricular  fibrillation.26 
Intravenous  dronedarone  was  more  effective  than 
intravenous amiodarone in a rat model of ischemia 
and    reperfusion-induced  arrhythmias.24  One  small 
study in implantable   cardioverter-defibrillator (ICD) 
patients showed no significant effect on defibrillation 
or pacing thresholds with doses up to 2000 mg/day. 
The ATHENA trial showed that dronedarone decrease 
cardiovascular mortality and a 45% reduction in sud-
den death. The effect of dronedarone on ventricular 
arrhythmias needs to be further studied in random-
ized trial. In the meantime, many physicians have 
treated patients with recurrent ICD shocks and con-
comitant ventricular arrhythmias with dronedarone. 
Sanofi is developing celivarone, a dronedarone ana-
log, for the treatment of ventricular arrhythmias and 
no further large prospective trials are planned with 
dronedarone.
Major Ongoing Trials
ArTEMIS
Amiodarone is effective in suppressing AF in about 
65% of patients but is often stopped secondary to inef-
ficacy and adverse effects. Due to the risk of torsade 
de pointes associated with these drugs, and the long 
half-life  of  amiodarone,  physicians  have  typically 
waited a month or more to start dofetilide or sotalol 
after stopping amiodarone. There is limited data from 
ATHENA and EURIDIS/ADONIS that patients can 
switch from amiodarone to dronedarone with mini-
mal delay. In the ATHENA trial, patients had to stop 
amiodarone at least a month prior to enrollment in 
the trial. The earlier EURIDIS and ADONIS trials 
allowed patients to be enrolled immediately after dis-
continuation of amiodarone. Physicians are currently 
using their clinical judgment in deciding the optimal 
amiodarone washout period for each patient. n order 
to study the safety of this switch ARTEMIS is loading 
over 800 persistent AF patients with oral amiodarone 
for a month and following cardioversion are switching 
patients to dronedarone immediately, after one week 
and after one month. This study will help determine 
the safety of such antiarrhythmic drug switches.
pALLAS
In a post-hoc analysis of ATHENA, dronedarone con-
tinued to demonstrate a benefit on decreasing cardio-
vascular hospitalizations in patients who developed 
permanent AF during the course of the study. Thus, 
decreased hospitalization may not be all secondary 
to preventing AF/AFl recurrences. Because of this Dronedarone for atrial fibrillation/flutter
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and  in  an  attempt  to  better  understand  the  benefit 
of   dronedarone, PALLAS planned to enroll 10,800 
patients  with  permanent  AF/AFl  and  randomizing 
patients to dronedarone 400 mg twice daily with meals 
versus placebo. The co-primary composite endpoints 
of this study include: (1) first stroke, systemic arte-
rial  embolism,  myocardial  infarction  or  cardiovas-
cular death; and, (2) first unplanned cardiovascular 
hospitalization or death from any cause. This study 
was  prematurely  halted,  after  3,149  patients  were 
enrolled, due to a two-fold increase in cardiovascu-
lar events (death, stroke, and hospitalization for heart 
failure) in the dronedarone arm of the study.63
HESTIA
The  Effects  of  Dronedarone  on  Atrial  Fibrillation 
Burden  in  Subjects  with  Permanent  Pacemakers 
(HESTIA) is a placebo controlled multicenter study 
assessing the effects of 400 mg twice daily of drone-
darone  on AF  burden  utilizing  pacemaker  electro-
gram data. The study duration is 12 weeks. The use of 
pacemaker electrograms will provide information on 
AF duration, frequency and relationship between AF 
burden and the patients’ perceived AF burden. This 
study started in July 2010.
Clinical Role of Dronedarone
In  the  USA,  the  Food  and  Drug  Administration 
approved dronedarone on March 18, 2009, to reduce 
the risk of cardiovascular hospitalization in patients 
with paroxysmal or persistent atrial fibrillation or atrial 
flutter. In Europe the drug was approved for rhythm 
and rate control of AF. Some advantages of this new 
antiarrhythmic drug include ease of initiation, as well 
as less surveillance for end organ toxicity than amio-
darone. There is a single recommended dose which 
can be started as an outpatient due to the low risk 
of proarrhythmia. While electrocardiograms should 
be periodically obtained, no chest x-rays or thyroid 
monitoring is required. Due to recent reports of possi-
ble rare hepatocellular injury, baseline liver function 
tests with periodic post-initiation checks are recom-
mended. Since there is no significant interaction with 
warfarin, more frequent monitoring of INRs is not 
needed. Dronedarone can increase the blood levels of 
dabigatran and this interaction should be considered 
in  patients  taking  concomitant  therapy  with  these 
two drugs. Dronedarone is generally well tolerated. 
  Gastrointestinal side effects are the most common, 
but were responsible for discontinuation of the drug 
in only 3.2% of patients in clinical trials. In our expe-
rience, the rate of discontinuation from diarrhea and 
GI side effects is higher than this.
These factors, along with fewer hospitalizations and 
decreased stroke risk seen in the ATHENA trial, may 
result in decreased cost of treatment in dronedarone 
patients. On the other hand, DIONYSOS and other 
meta-analyses  have  shown  dronedarone  to  be  less 
effective  than  amiodarone  in  preventing  recurrence 
of AF. Also, it was found to be unsafe for decompen-
sated heart failure patients in the ANDROMEDA trial.
Although less efficacious than amiodarone in the 
prevention of recurrent AF, dronedarone appears to be 
a safer, well-tolerated drug in patients with preserved 
left ventricular function. Dronedarone can be consid-
ered as an alternative therapy to amiodarone, and used 
prior to amiodarone, especially in younger patients. 
Dronedarone is also an obvious choice for patients who 
have develop end-organ toxicity from amiodarone.
Conclusion
Dronedarone is a first line therapy for patients with 
AF/AFl in patients.64,65 The highest benefit/lowest risk 
patients appear to be those with structural heart disease, 
who have a preserved ejection fraction and no recent 
decompensated heart failure. Although it is less effica-
cious than amiodarone in maintaining sinus rhythm, 
its effectiveness is similar to the other antiarrhythmic 
drugs used to treat AF. Dronedarone has rate control 
properties that may help improve rate control in refrac-
tory patients and decrease their symptoms. However, 
the results of PALLAS suggest the drug should not be 
used in the long-term rate control of permanent AF 
patients. In the ATHENA-like population, the drug’s 
cost can be counterbalanced by the lower cost of hos-
pitalization. Based on ANDROMEDA, dronedarone 
should  not  be  used  in  patients  with  CHF  NYHA 
class III-IV and left ventricular systolic   dysfunction. 
  Dronedarone provides an additional option for patients 
with AF and can be considered earlier in the treatment 
algorithm than amiodarone in most patients except for 
those with advanced heart failure.
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